Skip to main content

Research Repository

Advanced Search

Outputs (473)

ERS international Congress 2023: highlights from the Basic and Translational Sciences Assembly (2023)
Journal Article
Reddy, K. D., Bizymi, N., Schweikert, A., Ananth, S., Lim, C. X., Lodge, K. M., …Cuevas-Ocaña, S. (2024). ERS international Congress 2023: highlights from the Basic and Translational Sciences Assembly. ERJ Open Research, 10(2), https://doi.org/10.1183/23120541.00875-2023

Early career members of Assembly 3 (Basic and Translational Sciences) of the European Respiratory Society (ERS) summarise the key messages discussed during six selected sessions that took place at the ERS International Congress 2023 in Milan, Italy.... Read More about ERS international Congress 2023: highlights from the Basic and Translational Sciences Assembly.

Evolution of Treatment Targets in Inflammatory Bowel Disease (2023)
Journal Article
Kyriacou, M., Vuyyuru, S., & Moran, G. (2023). Evolution of Treatment Targets in Inflammatory Bowel Disease. Medical Research Archives, 11(11), https://doi.org/10.18103/mra.v11i11.4662

Inflammatory Bowel Disease (IBD), which encompasses Crohn's disease and ulcerative colitis, represents a chronic and progressive condition characterised by periods of active inflammation interspersed with periods of remission. The r... Read More about Evolution of Treatment Targets in Inflammatory Bowel Disease.

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. (2023)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., …Smyth, A. R. (2023). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. NIHR Open Research, 3(65), 1-16. https://doi.org/10.3310/nihropenres.13510.1

Background People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung fun... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes..

Multiparametric Renal Magnetic Resonance Imaging for Prediction and Annual Monitoring of the Progression of Chronic Kidney Disease over Two Years (2023)
Journal Article
Buchanan, C. E., Mahmoud, H., Cox, E. F., Prestwich, B. L., Noble, R. A., Selby, N. M., …Francis, S. T. (2023). Multiparametric Renal Magnetic Resonance Imaging for Prediction and Annual Monitoring of the Progression of Chronic Kidney Disease over Two Years. Journal of Clinical Medicine, 12(23), Article 7282. https://doi.org/10.3390/jcm12237282

Background: Multiparametric renal Magnetic Resonance Imaging (MRI) provides a non-invasive method to assess kidney structure and function, but longitudinal studies are limited. Methods: A total of 22 patients with CKD category G3-4 (estimated glomeru... Read More about Multiparametric Renal Magnetic Resonance Imaging for Prediction and Annual Monitoring of the Progression of Chronic Kidney Disease over Two Years.

Feedback control in hemodialysis (2023)
Journal Article
Randhay, A., Tarek Eldehni, M., & Selby, N. M. (2023). Feedback control in hemodialysis. Seminars in Dialysis, https://doi.org/10.1111/sdi.13185

A number of systems of feedback control during dialysis have been developed, which have the shared characteristic of prospectively measuring physiological parameters and then automatically altering dialysis parameters in real time according to a pre-... Read More about Feedback control in hemodialysis.

Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite (2023)
Journal Article
Ali, R., Alhaj Sulaiman, A., Memon, B., Pradhan, S., Algethami, M., Aouida, M., …Ramotar, D. (2023). Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite. Cells, 12(23), Article 2682. https://doi.org/10.3390/cells12232682

Targeting tumour metabolism through glucose transporters is an attractive approach. However, the role these transporters play through interaction with other signalling proteins is not yet defined. The glucose transporter SLC2A3 (GLUT3) is a member of... Read More about Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite.

Using a machine learning model to risk stratify for the presence of significant liver disease in a primary care population (2023)
Journal Article
Bennett, L., Mostafa, M., Hammersley, R., Purssell, H., Patel, M., Street, O., …Guha, I. N. (2023). Using a machine learning model to risk stratify for the presence of significant liver disease in a primary care population. Journal of Medical Artificial Intelligence, 6, Article 27. https://doi.org/10.21037/jmai-23-35

Background: Current strategies for detecting significant chronic liver disease (CLD) in the community are based on the extrapolation of diagnostic tests used in secondary care settings. Whilst this approach provides clinical utility, it has limitatio... Read More about Using a machine learning model to risk stratify for the presence of significant liver disease in a primary care population.

The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion (2023)
Journal Article
Aljohani, A., Alsaeed, S., Toss, M., Raafat, S., GREEN, A., & Rakha, E. (2023). The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion. American Journal of Cancer Research, 13(11), 5334–5351

Lymphovascular invasion (LVI) is a common phenomenon in breast cancer (BC), and it is correlated to poor outcome. However, the biomarkers that influence the development of LVI remain to be defined. Through rigorous bioinformatics analyses, high mobil... Read More about The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., …Linton, K. M. (2023). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.